Cat#: EV-059-0273-A1 (1 x 10^9 EVs in 100 µl buffer), EV-059-0273-A2 (5 x 10^9 EVs in 50 µl buffer)Origin/cell factory:
human Wharton´s Jelly derived MSCs (Cat# CHT-021-0273)Enrichment/storage medium:
tangential flow filtration, 20 mM HEPES
100-200 nm, 400 µg protein (1 x 10^9 EVs), sterile, Endotoxin level < 0.01 EU/ml
research&development, not for clinical use
Presence of typical EV marker proteins
EVs derived from WJ-MSC/TERT273 cells carry typical surface proteins such as CD81 and Syntenin. EVs do not carry Calnexin as shown by western blotting.
Morphology of extracellular vesicles from WJ-MSC/TERT273
EVs derived from WJ-MSC/TERT273 cells show the typical EV morphology with lipide double layer membrane as demonstrated by cryo electron microscopy (cryo EM).
Anti-inflammatory activity of extracellular vesicles from WJ-MSC/TERT273
Treatment of mouse macrophage cells (RAW264.7) with lipopolysaccharide (LPS) induces the formation of nitric oxide (NO) formation indicating an inflammatory reaction.
Addition of extracellular vesicles from Wharton´s Jelly derived mesenchymal stem cells significantly reduces NO formation demonstrating anti-inflammatory activity of extracellular vesicles from Wharton´s Jelly derived mesenchymal stem cells in vitro.
Anti-fibrotic activity of extracellular vesicles from WJ-MSC/TERT273
Treatment of human fibroblasts (fHDF/TERT166) with Transforming Growth Factor beta (TGF-ß) induces the expression of alpha smooth muscle actin (𝛂-SMA) indicating myofibroblast differentiation/activation, which is a key event in physiological and pathological tissue repair.
Addition of extracellular vesicles from Wharton´s Jelly derived mesenchymal stem cells significantly reduces expression of 𝛂-SMA indicating anti-fibrotic activity of extracellular vesicles from Wharton´s Jelly derived mesenchymal stem cells in vitro.
Fibroblast growth promoting activity of extracellular vesicles from WJ-MSC/TERT273
Treatment of human fibroblasts (fHDF/TERT166), grown in an in vitro wound healing / scratch assay with extracellular vesicles from Wharton´s Jelly derived MSCs (EV-WJ) induces cell migration even better as control medium (w/o EVs). On the contrary, exosomes derived from adipose-derived MSCs (Evs-ASC) did not induce fibroblast growth.
These data indicate fibroblast growth promoting / wound healing activity of extracellular vesicles from Wharton´s Jelly derived mesenchymal stem cells.
Neo-angiogenic potential of extracellular vesicles from WJ-MSC/TERT273
Treatment of endothelial spheroids with vascular endothelial growth factor (VEGF) induces the formation of sprouts indicating neo-angiogenic potential.
A similar effect is detected when spheroids are treated with extracellular vesicles derived from our Wharton´s Jelly derived mesenchymal stem cells WJ-MSC/TERT273.
No sprout formation is detected when spheroids are treated with EVs from endothelial cells HUVEC/TERT2.
Counteracting anti-angiogenic effect of drugs
Treatment of endothelial spheroids with vascular endothelial growth factor (VEGF) induces the formation of sprouts, whereby sprout formation is inhibited upon treatment with cyclosporin A.
Anti-angiogenic effect of cyclosporin A is inhibited by addition of extracellular vesicles from Wharton´s Jelly mesenchymal stem cells.
miRNA cargo of extracellular vesicles from WJ-MSC/TERT273
Extracellular vesicles were produced using a hollow fiber bioreactor, whereby supernatants were harvested 1-2 times per week over a period of 3-4 months.
After enrichment of particles by tangential flow filtration (TFF) and RNA isolation, a panel of microRNAs was analyzed.
During the whole production process the EV cargo of analyzed miRNAs is very stable.
Upon arrival immediately transfer the product to -80°C.
Store product at -80°C (for up to 6 months) until use.
Thaw the EVs on ice, centrifuge before opening the tube to ensure that the solution is collected at the bottom of the tube. Then, mix carefully by pipetting up and down and aliquot for further use to avoid multiple freeze thaw cycles.
Store the aliquots at -80°C until use.
After thawing, store the EVs at 4°C for a maximum of 1 day.
Product data sheet – certificate of analysis
is available upon request | Please contact us indicating the respective LOT numbers
Data on Markers and Functions
Study of wound healing
Development of new anti-inflammatory drugs
Development of a new therapy for the treatment of COVID-19
Selected publications: exosomes for the treatment of COVID-19
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. (2020) Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020 Jun 15;29(12):747-754. https://pubmed.ncbi.nlm.nih.gov/32425691/
Verena Börger V, Weiss DJ, Anderson JD, Borràs FE, Bussolati B, Carter DRF, Dominici M, Falcón-Pérez JM, Gimona M, Hill AF, Hoffman AM, de Kleijn D, Levine BL, Lim R, Lötvall J, Mitsialis SA, Monguió-Tortajada M, Muraca M, Nieuwland R, Nowocin A, O’Driscoll L, Ortiz LA, Phinney DG, Reischl I, Rohde E, Sanzenbacher R, Théry C, Toh WS, Witwer KW, Lim SK, Giebel B. (2020) International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. Cytotherapy. 22(9):482-485. https://pubmed.ncbi.nlm.nih.gov/32425691/
Selected publications: exosomes for the treatment of wounds
Casado-Díaz A, Quesada-Gómez JM, Dorado G. (2020) Extracellular Vesicles Derived From Mesenchymal Stem Cells (MSC) in Regenerative Medicine: Applications in Skin Wound Healing. Front Bioeng Biotechnol. 8:146. https://pubmed.ncbi.nlm.nih.gov/32195233/